Fangqiang Tang

Fangqiang Tang is a Senior Scientist at Agenus, specializing in strategy development for CHO cell line development focused on immunotherapy antibodies. Previously, Fangqiang held the position of Principal Scientist 2 at ExecuPharm, concentrating on cell line development. Experience includes a Senior Scientist role at NovaRock Biotherapeutics Ltd, where Fangqiang engaged in cell engineering and function assay development for cancer immunotherapy. Prior postdoctoral research positions at Cleveland Clinic Foundation, Case Western Reserve University, and the University of Toledo involved investigating various biological regulatory mechanisms and their implications for health. Fangqiang holds a Doctor of Philosophy in Microbiology and Virology from Wuhan University and a Master's degree in Veterinary Preventive Medicine from Sichuan Agricultural University.